Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMDW) Preferred Stock Liabilities (2018 - 2019)

Historic Preferred Stock Liabilities for Revolution Medicines (RVMDW) over the last 2 years, with Q4 2019 value amounting to $305.1 million.

  • Revolution Medicines' Preferred Stock Liabilities rose 4877.49% to $305.1 million in Q4 2019 from the same period last year, while for Dec 2019 it was $305.1 million, marking a year-over-year increase of 4877.49%. This contributed to the annual value of $305.1 million for FY2019, which is 4877.49% up from last year.
  • Revolution Medicines' Preferred Stock Liabilities amounted to $305.1 million in Q4 2019, which was up 4877.49% from $305.1 million recorded in Q3 2019.
  • Revolution Medicines' Preferred Stock Liabilities' 5-year high stood at $305.1 million during Q3 2019, with a 5-year trough of $205.1 million in Q4 2018.